Latest Earnings Results: Q3 '26
Estimated EPS
-$0.39
Reported EPS
-$0.35
Surprise
+9.93%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.35 up 20.45% YoY • Acumen Pharmaceuticals expects its $78.6M in cash, cash equivalents and marketable securities as of September 30, 2026, to support current clinical and operational activities into early 2027.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.40 | -- | -- | N/A |
Q3 '26 | -$0.39 | -$0.35 | 9.93% | BEAT |
Q2 '26 | -$0.36 | -$0.45 | -25.23% | MISSED |
Q1 '26 | -$0.40 | -$0.33 | 18.07% | BEAT |
Q4 '25 | -$0.46 | -$0.40 | 12.98% | BEAT |